Primary Investigator

Jonathan Silverberg, MD, PhD, MPH

Dr. Silverberg specializes in dermatoepidemiology with a focus on comorbidities and quality of life. His research interests include the patient-and-population-based burden of atopic dermatitis and other chronic inflammatory skin diseases.

Study Sponsored By:

Eli Lilly and Company

Lilly

Interested?

Schedule your screening visit to find out if you are eligible to participate in BREEZE-AD5 by contacting our study team at:

1-312-503-5945

NUderm-research@northwestern.edu

Who We Are

About Us

Our clinical dermatopharmacology unit consists of an active clinical trials group for industry-sponsored studies as well as investigator-initiated outcomes research.

Contact Us

Northwestern University
Department of Dermatology
Clinical Trials Unit

676 N. St. Clair Street. Suite 1600
Chicago, IL 60611

Visit us online:
www.tinyurl.com/NUFeinbergCTU

Northwestern Medicine®
Feinberg School of Medicine

BREEZE-AD5

A research study on atopic dermatitis / eczema

Participants Invited

About BREEZE-AD5

BREEZE-AD5 is a clinical research study that will look at how safe and effective an oral investigational medication is in helping to relieve the symptoms of moderate to severe atopic eczema (also known as atopic dermatitis).

During this study, 1 out of every 3 participants will take a placebo. Placebo-controlled studies like this one (where some participants receive the investigational medication and some receive a placebo), help us make sure that any effects we see are due to taking the investigational medication and not to other factors.

As part of your participation, you will be asked to attend clinic visits up to 16 times to assess your health closely and see how you are responding to your assigned dosing plan.

To monitor your health throughout the study, you will be asked to keep a daily electronic diary (eDiary) about your condition and your medication use. Secondly, your health will be assessed to see how you are responding to your assigned dosing plan through the following assessments:

- Vital signs checks (your blood pressure and heart rate)
- Blood tests
- Weight measurements
- Questionnaires about your general health and atopic eczema
- A review of your eDiary

Eligibility Criteria

- ✓ Age 18 and above
- ✓ Have a diagnosis of atopic dermatitis (AD) for at least one year prior to study

Participants are needed for a study evaluating the effectiveness and safety of an investigational medication on individuals with moderate to severe atopic dermatitis

- ✓ Have had inadequate response to treatment with topical medication or for whom topical treatment are medically inadvisable within the last 6 months.
- ✓ AD involvement of ≥10% body surface area at screening and at randomization
- ✓ Agree to apply emollients daily for at least 14 days before randomization and agree to use emollient throughout the treatment period
- ✓ Agree to discontinue use of excluded medications/treatment for at least 4 weeks before randomization
- ✓ Use effective birth control for those of child bearing potential

Join a Clinical Study Investigating the Treatment of Eczema

Length of Participation

Participation in BREEZE-AD5 will be approximately 2 years and 2 months. Participants will be required to visit the dermatology clinic at the downtown Chicago area for in-person assessments and study drug administration.

The study is split into three periods:

- A **screening period** of up to 5 weeks
- A **dosing period** of up to 2 years
- A **follow-up period** of 4 weeks after the last study drug dose

Participants will be compensated.